MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur’s agreement to develop and commercialise MEDI8897.

Paolo Bossi

Gowling WLG has advised on the transaction MEDI8897 is a monoclonal antibody for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

…

This content is for Standard 1 Year members only.
Login Join Now